Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 17/20 | 0.49 |
| ▸ | EDNRB | P24530 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257596 | 0.90 | DHPS (0.52) | EDNRAEDNRBDHPS | |
| SCHEMBL9423634 | 0.87 | FFAR1 (0.51) | — | |
| SCHEMBL7296266 | 0.86 | DHPS (0.43) | EDNRAEDNRBCYP19A1DHPS | |
| SCHEMBL7942227 | 0.84 | HPGD (0.45) | EDNRAEDNRBCYP19A1 | |
| SCHEMBL28568819 | 0.83 | DHPS (0.59) | DHPS | |
| SCHEMBL4061462 | 0.82 | DHPS (0.49) | EDNRAEDNRBDHPS | |
| SCHEMBL7483960 | 0.82 | HTT (0.48) | DHPS | |
| SCHEMBL618135 | 0.81 | DHPS (0.58) | EDNRAEDNRBDHPS | |
| SCHEMBL29770374 | 0.81 | DHPS (0.58) | EDNRAEDNRBDHPS | |
| SCHEMBL7694584 | 0.80 | EDNRB (0.44) | EDNRAEDNRBDHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240470-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN Laboratories Limited (IN) | 2010-10-20 | — | — | EP | claimed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| EP-2768812-A1 | ACID ADDITION SALTS OF BOSENTAN | Biocon Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057545-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057545-A1 | ACID ADDITION SALTS OF BOSENTAN | BIOCON LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | disclosed |
| WO-2002083650-A1 | NOVEL SULFONYLAMINO-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
| WO-2001081335-A1 | PYRIMIDINE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001081338-A1 | SUBSTITUTED SULFONYLAMINOPYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-11-01 | — | — | WO | disclosed |
| EP-1137642-A1 | BIS-SULFONAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001046156-A1 | BUTYNE DIOL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CYP2D6, CYP3A5, QDPR | EDNRA 146/4885EDNRB 13/4885CYP19A1 1620/4885 |
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | EDNRA 3/4885EDNRB 2/4885CYP19A1 269/4885 |
| US-20140275535-A1 | ACID ADDITION SALTS OF BOSENTAN | NCLN, EDNRB, EDNRA | EDNRA 3/4885EDNRB 2/4885CYP19A1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.